BPC-157
Coverage of BPC-157 in the Nexus archive.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA's upcoming peptide safety review panel includes health professionals with financial ties to the peptide industry, a shift from previous academic-focused panels. The meeting, influenced by Health Secretary Robert F. Kennedy Jr.'s 'Make America Healthy Again' movement, will assess peptides like BPC-157 and TB-500, which the FDA has warned are unproven and risky.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA will convene a panel to review the safety of popular peptide injections, with participants including doctors and pharmacists financially tied to the peptide industry. The meeting, part of efforts to reshape health policy under Robert F. Kennedy Jr., will assess peptides like BPC-157 and TB-500, which the FDA has previously warned are unapproved and risky.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA's upcoming panel to review controversial peptide drugs includes health professionals with financial ties to the industry, including clinics and pharmacies promoting unproven peptides. The meeting follows concerns about the safety and regulatory status of substances like BPC-157 and TB-500, which are marketed for wellness purposes but lack scientific validation. Health Secretary Robert F. Kennedy Jr. has publicly supported these peptides.
- The hidden history of BPC-157, a favorite MAHA peptide
The article discusses the hidden history of BPC-157, a MAHA peptide, tracing its origins to an idea formed by Predrag Sikiric in 1975 during his time in Yugoslavia. The piece is co-published by STAT and Undark with support from the Pulitzer Center.
- Thinking about peptides? Doctors reveal key dos and don’ts as ‘Wild West’ market grows
The peptide market is expanding rapidly, driven by popularity among wellness influencers and claims of benefits like muscle growth and anti-aging. However, many peptides lack FDA safety and efficacy oversight, raising concerns as the FDA considers easing restrictions. Experts warn of risks from unregulated products and emphasize the need for clinical rationale and professional guidance.
- RFK Jr.'s peptide push could become next wellness boom
RFK Jr. advocates for loosening federal restrictions on peptides, potentially boosting telehealth companies, compounding pharmacies, and longevity clinics. The FDA will review peptide regulations in July, while experts debate their efficacy and safety, with market projections reaching $180 billion in five years.
- Peptides may soon be easier to get amid RFK Jr's push, but experts warn of risks
The FDA is considering easing restrictions on peptides in a July meeting, influenced by Health and Human Services Secretary Robert F. Kennedy Jr.'s push for deregulation. Peptides, used for conditions like insomnia and obesity, face safety concerns despite their popularity among wellness influencers. Experts warn of risks due to limited FDA review.
- FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures
The FDA plans to review easing restrictions on seven peptides, including BPC-157 and TB-500, amid pressure from Health Secretary Robert F. Kennedy Jr. and his allies. Critics warn that unregulated peptide use poses significant safety risks, as these substances lack clinical testing and FDA approval.